Liendax

Liraglutide, the active ingredient in Liendax, is a GLP‑1 receptor agonist presented as a sterile solution for subcutaneous use. It is indicated for the management of type 2 diabetes mellitus in adult patients, improving glycaemic control when used alongside diet and exercise. GNH USA supplies Liendax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides cold‑chain logistics for injectable products. Customers receive regulatory documentation and batch release certificates to support import and clinical use.

Liraglutide, a GLP‑1 receptor agonist, is employed to improve glycaemic control in type 2 diabetes.

- Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels when used alone. - Type 2 diabetes mellitus (combination therapy): enhances the effect of metformin or other oral agents to achieve target HbA1c. - Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise interventions to improve overall metabolic control.

Liraglutide may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Vomiting - Diarrhoea - Constipation - Headache - Injection site reactions

Serious or Rare Side Effects: - Pancreatitis - Severe hypoglycaemia (especially with insulin or sulfonylureas) - Gallbladder disease or cholelithiasis - Acute kidney injury - Allergic reactions including anaphylaxis - Thyroid C‑cell tumours (observed in rodent studies)

When prescribing liraglutide, clinicians should consider several safety precautions.

- Renal function: assess baseline renal function and monitor periodically. - Pancreatitis: advise patients to report persistent abdominal pain. - Thyroid disease: avoid in individuals with a history of medullary thyroid carcinoma or MEN 2. - Pregnancy: use only if the potential benefit outweighs the potential risk. - Drug interactions: review concomitant medications for hypoglycaemia risk. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Liraglutide can interact with other medicines, requiring attention to avoid or monitor effects.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Other GLP‑1 agonists (e.g., exenatide): concurrent use may amplify gastrointestinal effects. - Medications that delay gastric emptying: may enhance nausea or vomiting.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as liraglutide may affect coagulation parameters. - Beta‑blockers: may mask symptoms of hypoglycaemia. - Diuretics: monitor renal function and electrolytes during therapy.